Eur. J. Cancer 2015-03-01
Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year survival analysis of a phase 3 randomised controlled trial.
Abstract
Background
Accelerated partial breast irradiation (APBI) has been introduced as an alternative treatment method for selected patients with early stage breast cancer (BC). Intensity-modulated radiotherapy (IMRT) has the theoretical advantage of a further increase in dose conformity compared with three-dimensional techniques, with more normal tissue sparing. The aim of this randomised trial is to compare the local recurrence and survival of APBI using the IMRT technique after breast-conserving surgery to conventional whole-breast irradiation (WBI) in early stage BC.
Methods
This study was performed at the University of Florence (Florence, Italy). Women aged more than 40years affected by early BC, with a maximum pathological tumour size of 25mm, were randomly assigned in a 1:1 ratio to receive either WBI or APBI using IMRT. Patients in the APBI arm received a total dose of 30 Gy to the tumour bed in five daily fractions. The WBI arm received 50Gy in 25 fractions, followed by a boost on the tumour bed of 10Gy in five fractions. The primary end-point was occurrence of ipsilateral breast tumour recurrences (IBTRs); the main analysis was by intention-to-treat. This trial is registered with ClinicalTrials.gov, number NCT02104895.
Findings
A total of 520 patients were randomised (260 to external WBI and 260 to APBI with IMRT) between March 2005 and June 2013. At a median follow-up of 5.0 years (Interquartile Range (IQR) 3.4-7.0), the IBTR rate was 1.5% (three cases) in the APBI group (95% confidence interval (CI) 0.1-3.0) and in the WBI group (three cases; 95% CI 0.0-2.8). No significant difference emerged between the two groups (log rank test p=0.86). We identified seven deaths in the WBI group and only one in the APBI group (p=0.057). The 5-year overall survival was 96.6% for the WBI group and 99.4% for the APBI group. The APBI group presented significantly better results considering acute (p=0.0001), late (p=0.004), and cosmetic outcome (p=0.045).
Interpretation
To our knowledge, this is the first randomised study using the IMRT technique for APBI delivery. No significant difference in terms of IBTR and overall survival was observed between the two arms. APBI displayed a significantly better toxicity profile.
Related Questions
Have the 10-year results from UK FAST-Forward impacted your practice with regard to patient selection?
I would consider our practice at Mayo as early adopters of ultra-hypofractionation for breast, largely driven by similar institutional trials for shorter courses and the patients we care for. As a result, we have pretty routinely offered 26 Gy/5 fraction whole breast RT since the 5-year follow-up wa...
With the presentation of HypoG-01 phase III UNICANCER trial at ESMO 2024, should hypofractionated radiotherapy be the standard across the board for breast cancer?
It would be difficult not to recommend at this time.HypoG-01 had broad criteria and did not show any differences in outcomes in terms of disease control or toxicity between 40/15 vs 50/25. RT-CHARM was all reconstructed PMRT patients showed a slightly higher risk of complications with the hypofracti...
Do you prefer to use the FAST or FAST-Forward regimen when treating stage I breast cancer with an ultra-hypofractionated approach?
We favor APBI like the Florence regimen but if technically not suitable, then FAST-Forward.
Would you consider radiation omission for a patient with a Stage I breast cancer with an elevated Oncotype Dx?
I would offer the patient treatment based on the fact that she is in her 60s with a presumably long life expectancy, a high grade lesion, and radiation will lower her risk of local recurrence significantly. Even with a lower Oncotype, radiation will lower the risk of recurrence significantly accordi...
What percentage of your breast cancer patients do you plan using IMRT vs 3D?
I think this happens to hinge on your definition of IMRT. Until it became a billing issue, FiF/forward planned segmented treatments were known as IMRT. When it became concerning that billing these as IMRT would become costly for Medicare and commercial payors, the radiation oncology did some sleight...
Should BED or EQD2 be used when deciding on a fractionation scheme for breast cancer radiation, and should tumor or normal tissue be prioritized in this consideration?
I feel, with many prospective randomized data, we are beyond looking at EQ2 dose for deciding fractionation. We follow the below rationale/pathway in our practice. Is biology suitable for PBI or not? (If suitable then plan for 30 Gy in 5 fractions like Italian data) Biology is suitable for PBI but ...
Is it acceptable to offer 26 Gy in 5 fractions for APBI rather than whole-breast RT?
Yes. We know 26/5 works for whole breast, either daily or weekly fractionation schedules. So, one can utilize that in patients that are APBI candidates. That being said, the toxicity data from Florence trial and my personal experience are excellent, so I do a hybrid approach. I give 26/5 to a larger...
Would you consider APBI using the Florence regimen in patients with preexisting breast implants?
There is data on using other APBI techniques with preexisting implants, ex. interstitial brachytherapy.I have used Florence regimen on patients with implants but counseled they were not included in the study and warn about the risk of capsular contracture.
Should SBRT for bone metastasis be delivered daily, or every other day?
Canadian/Australian study gave 24 Gy in 2 fractions on consecutive days and no excessive toxicity was noted.I schedule them daily, but if there is a patient convenience issue, QOD is reasonable.It is very interesting, however - there is conflicting data on the efficacy of QD vs QOD for SBRT for lung...
How does one interpret the LUMINA trial in the FLORENCE APBI ERA?
This is a common scenario. My practice is to discuss this with the patient. I discuss 5 fraction PBI or 5 fraction WBI depending on the scenario, as well as endocrine therapy and the differences in toxicity profiles. Given compliance rates of 50-60% with endocrine therapy long-term, many patients pr...
When evaluating margin status to consider APBI for early stage invasive breast cancer, given the specification for at least 2 mm margins, do you look at the DCIS margin or only the invasive margin?
I take a slightly different approach. Current guidelines for breast conserving surgery allow for no tumor on ink for invasive cancers, even those with DCIS associated. While ASTRO guidelines recommend 2 mm for APBI (Correa et al., PMID 27866865), other guidelines such as the ABS do not for invasive ...
Given UK FAST Forward data for whole breast, would you consider this daily 1 week fractionation scheme when treating with partial breast approach?
I use the Livi regimen daily rather than other day and it has worked well. I use IMRT. You could also consider 27/5 based on ACCEL study, though follow-up was short.
What lung constraints do you use for early stage breast hypofractionation?
The rationale for monitoring/constraining the ipsilateral lung is to avoid symptomatic radiation pneumonitis. That being said, I don't know if I have ever seen it in a patient where we are not treating nodes.Our official scorecard for whole breast conventional fractionation (40-42.56 Gy/15-16 fx) st...
Do you always use the same CTV and PTV expansions when defining fields for lumpectomy bed boost?
If using electron beams, we expand by 2 to 2.5 cm (based on electron energy) around the lumpectomy cavity. If using photons, then we use 1 cm for CTV and 3 mm for PTV.
How do you deliver whole breast radiation to a woman with pectus excavatum?
Agree that these can be challenging cases. The technique used depends on the severity of the pectus deformity, need to treat regional nodes (particularly IMNs), and need to treat the whole breast.@Dr. First Last's advice is sound regarding multiple different plans may be needed and then the optimal ...
How do results from NSABP B-39 influence your practice for APBI compared to WBI in early stage breast cancer?
With respect to clinical outcomes, the results of B-39 confirm what the data previously available demonstrated. APBI is an appropriate option for appropriately selected patients. A less than 5% recurrence at 10 years is excellent and paired with the updated RAPID results provide confidence that part...
Would you consider hypofractionated weekly whole breast irradiation for early stage breast cancer?
A word of warning to those who are still "struggling" with the concept of modest, daily HFRT for post-menopausal, biologically-favorable early-stage breast cancer, your mind is about to be blown...FAST! "Once a week??!! Where did this come from??!" is a question I've heard not a few people asking ov...
What are your considerations in choosing partial breast irradiation versus external beam hypofractionated whole breast RT for early stage breast cancer?
Accelerated partial breast irradiation has become a standard of care option for appropriately selected patients. Currently, patients who can be offered APBI come from the ASTRO guidelines or the more recently updated ABS partial breast guidelines released.In general, I will consider APBI for node ne...
What strategies do you use for large breasted women receiving whole breast radiation?
If we can't do prone, we use a styroform wedge in the inframammary region to decrease the breast fold and thus, decrease the inferior margin and amount of inframammary fold we have to treat. I would initially try hypofractionation with mixed beam with a field-in-field technique and if the dose homog...
Do you recommend omitting radiation therapy in young women with favorable DCIS?
If someone can get a screening mammogram, diagnostic mammogram, image-guided biopsy, segmental mastectomy, entertain a conversation about 5 years of ET, they can most certainly handle 5-15 days of PBI where the grade 0 toxicity rate is exceedingly high. Whole breast RT with the Whelan regimen is als...